Table 2.

Prescribed ESA dose quantiles by region

Month/Yeara	Scaled by Predialysis Weight						Not Scaled
	N	10th	25th	50th	75th	90th	N	10th	25th	50th	75th	90th
Europeb
08/2010	1528	33	56	101	175	274	1628	2500	4000	7500	11,997	19,663
12/2011	881	31	52	101	173	303	1419	2236	4000	6944	11,854	20,000
04/2013	1158	30	54	90	144	232	1338	2297	3900	6249	10,000	15,000
Japan
08/2010	832	26	41	76	124	193	872	1500	2500	3933	6525	10,000
12/2011	973	24	43	76	131	190	1020	1404	2500	4315	7500	10,000
04/2013	1092	30	51	88	136	192	1111	1774	2924	5000	7500	10,000
United States black
08/2010	825	49	88	167	317	554	833	4230	7229	14,250	25,230	46,087
12/2011	872	37	64	131	227	396	916	2933	4769	9523	17,415	30,782
04/2013	813	35	56	107	222	401	839	2918	4604	8655	18,262	31,751
United States nonblack
08/2010	1835	42	88	159	292	549	1883	3299	6522	12,467	23,077	43,786
12/2011	1744	36	61	115	214	361	1912	2933	4597	8416	16,025	27,526
04/2013	1481	24	46	94	176	328	1540	1983	3640	7311	13,735	24,334

Values expressed as iv epoetin–equivalent units per week were calculated using the following conversions: subcutaneous epoetin (×1.15), darbepoetin (×250 units/μg), and pegylated epoetin-β (×208 units/μg).

^aFacility sample transitioned from the DOPPS 4 to the DOPPS 5 during January to April of 2012.

^bEurope includes the DOPPS facility samples in Germany, Italy, Spain, and the United Kingdom.